S100A14在妇科肿瘤发生发展中的研究进展

目前生殖系统肿瘤占女性全身肿瘤的15%,临床上迫切需要寻找一种能指导治疗及评估预后的生物标志物。S100A14是钙结合蛋白家族成员之一,在多种肿瘤组织中表达异常,与肿瘤的发生、发展和侵袭、转移关系密切。近年来,越来越多的研究表明S100A14表达与妇科肿瘤的临床病理分期、分化程度及淋巴结转移具有相关性,有望成为一个特异性肿瘤标志物。目前S100A14在妇科肿瘤发生、发展进程中的作用机制尚不明确,较为接受的说法是S100A14通过激活相关细胞信号转导通路,导致相关细胞因子表达水平变化,从而影响细胞周期的正常调控。深入研究S100A14在妇科肿瘤中的作用机制,靶向干预其作用过程,可为临床治疗妇科肿瘤提供新思路。现就S100A14在妇科肿瘤中的表达情况及其作用机制进行综述。

Research Progress of S100A14 Protein in Gynecologic Oncology Development

At present, reproductive system tumors account for 15% of female systemic tumors, so there is an urgent need to find a biomarker that can guide treatment and evaluate prognosis. S100A14 protein is a member of the calcium-binding protein family and its expression is abnormal in many kinds of tumor tissues，which is closely related to the occurrence, development, invasion and metastasis of tumor. In recent years, more and more studies have shown that the expression of S100A14 is related to the clinicopathologic stage, differentiation and lymph node metastasis of gynecological tumors, and is expected to be a specific tumor marker. At present, the mechanism of S100A14 in the occurrence and development of gynecological tumors is not clear. It is accepted that S100A14 can activate the signal transduction pathway of related cells and cause the change of the expression level of related cytokines, so as to affect the normal regulation of the cell cycle. Further study on the mechanism of S100A14 in gynecological tumors and targeted intervention in the process of action can provide a new idea for clinical treatment of gynecological tumors. This article reviews the expression and mechanism of S100A14 in gynecological tumors.